--- title: "Fresenius SE & Co. (OTCMKTS:FSNUY) Releases Earnings Results, Misses Expectations By $0.01 EPS" type: "News" locale: "en" url: "https://longbridge.com/en/news/285473225.md" description: "Fresenius SE & Co. (OTCMKTS:FSNUY) reported quarterly earnings of $0.24 per share, missing the consensus estimate of $0.25 by $0.01. The company has a net margin of 5.71% and a return on equity of 10.31%. Despite the earnings miss, analysts maintain a \"buy\" rating on the stock, which is currently trading at $11.91 with a market capitalization of $26.83 billion. Fresenius operates in the healthcare sector, focusing on dialysis and medical care services." datetime: "2026-05-07T02:33:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285473225.md) - [en](https://longbridge.com/en/news/285473225.md) - [zh-HK](https://longbridge.com/zh-HK/news/285473225.md) --- # Fresenius SE & Co. (OTCMKTS:FSNUY) Releases Earnings Results, Misses Expectations By $0.01 EPS Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) posted its earnings results on Wednesday. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.25 by ($0.01), Zacks reports. Fresenius SE & Co. had a return on equity of 10.31% and a net margin of 5.71%. Get **Fresenius SE & Co.** alerts: ## Fresenius SE & Co. Price Performance FSNUY stock traded up $0.30 during mid-day trading on Wednesday, hitting $11.91. The stock had a trading volume of 70,514 shares, compared to its average volume of 142,768. The company has a current ratio of 1.32, a quick ratio of 1.00 and a debt-to-equity ratio of 0.47. Fresenius SE & Co. has a 52 week low of $11.28 and a 52 week high of $33.93. The firm has a market capitalization of $26.83 billion, a P/E ratio of 18.91 and a beta of 0.68. The firm has a fifty day simple moving average of $13.13 and a 200 day simple moving average of $14.16. ## Wall Street Analysts Forecast Growth A number of research firms recently commented on FSNUY. Citigroup reaffirmed a "buy" rating on shares of Fresenius SE & Co. in a research report on Tuesday, February 3rd. Morgan Stanley reaffirmed an "overweight" rating on shares of Fresenius SE & Co. in a research report on Monday, April 20th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock presently has an average rating of "Buy". **Check Out Our Latest Stock Analysis on Fresenius SE & Co.** ## Fresenius SE & Co. Company Profile (Get Free Report) Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world's leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella. The company operates through four main business segments. ## Featured Stories - Five stocks we like better than Fresenius SE & Co. _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ ## Should You Invest $1,000 in Fresenius SE & Co. Right Now? Before you consider Fresenius SE & Co., you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Fresenius SE & Co. wasn't on the list. While Fresenius SE & Co. currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [FSNUY.US](https://longbridge.com/en/quote/FSNUY.US.md) - [FRE.DE](https://longbridge.com/en/quote/FRE.DE.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [MS.US](https://longbridge.com/en/quote/MS.US.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) - [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md) - [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md) - [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md) - [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md) - [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md) - [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md) - [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md) - [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md) - [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md) ## Related News & Research - [Interested In Fresenius SE KGaA's (ETR:FRE) Upcoming €1.05 Dividend? You Have Three Days Left](https://longbridge.com/en/news/287156756.md) - [Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Unusually-High Trading Volume - Should You Buy?](https://longbridge.com/en/news/281561356.md) - [Top Ameriprise Executive Makes a Major Move With Insider Stock Sale](https://longbridge.com/en/news/286846818.md) - [Should You Think About Buying Synergie SE (EPA:SDG) Now?](https://longbridge.com/en/news/287156751.md) - [Fresenius SE Non-GAAP EPS of €0.82, revenue of €5.74B; reaffirms FY26 outlook](https://longbridge.com/en/news/285331311.md)